Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
Journal of the American College of Cardiology · 2023-05 · 81 (18) · 1780-1792
DOI: 10.1016/j.jacc.2023.02.050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American College of Cardiology, 2023-05. Verfasst von Thomas C Gilliland und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Program in Medical and Population Genetics and the Cardiovascular…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Cardiovascular Diseases. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Lipoprotein(a) (Lp[a]) and oxidized phospholipids (OxPLs) are each independent risk factors for atherosclerotic cardiovascular disease. The extent to which Lp(a) and OxPLs predict coronary artery disease (CAD) severity and outcomes in a contemporary, statin-treated cohort is not well established. OBJECTIVES: This study sought to evaluate the relationships between Lp(a) particle concentration and OxPLs associated with apolipoprotein B (OxPL-apoB) or apolipoprotein(a) (OxPL-apo[a]) with angiographic CAD and cardiovascular outcomes. METHODS: Among 1,098 participants referred for coronary angiography in the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) study, Lp(a), OxPL-apoB, and OxPL-apo(a) were measured. Logistic regression estimated the risk of multivessel coronary stenoses by Lp(a)-related biomarker level. Cox proportional hazards regression estimated the risk of major adverse cardiovascular events (MACEs) (coronary revascularization, nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) in follow-up. RESULTS: Median Lp(a) was 26.45 nmol/L (IQR: 11.39-89.49 nmol/L). Lp(a), OxPL-apoB, and OxPL-apo(a) were highly correlated (Spearman R ≥0.91 for all pairwise combinations). Lp(a) and OxPL-apoB were associated with multivessel CAD. Odds of multivessel CAD per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.10 (95% CI: 1.03-1.18; P = 0.006), 1.18 (95% CI: 1.03-1.34; P = 0.01), and 1.07 (95% CI: 0.99-1.16; P = 0.07), respectively. All biomarkers were associated with cardiovascular events. HRs for MACE per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.08 (95% CI: 1.03-1.14; P = 0.001), 1.15 (95% CI: 1.05-1.26; P = 0.004), and 1.07 (95% CI: 1.01-1.14; P = 0.02), respectively. CONCLUSIONS: In patients undergoing coronary angiography, Lp(a) and OxPL-apoB are associated with multivessel CAD. Lp(a), OxPL-apoB, and OxPL-apo(a) are associated with incident cardiovascular events. (Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA]; NCT00842868).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Ma…
- Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, California, USA.
- Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Baim Institute for Clinical Research, Boston, Massachusetts…
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Gilliland, T. C., Liu, Y., Mohebi, R., Miksenas, H., Haidermota, S., Wong, M., Hu, X., Cristino, J. R., Browne, A., Plutzky, J., Tsimikas, S., Januzzi, J. L., & Natarajan, P. (2023). Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. Journal of the American College of Cardiology, 81(18), 1780-1792. https://doi.org/10.1016/j.jacc.2023.02.050
Vancouver
Gilliland TC, Liu Y, Mohebi R, Miksenas H, Haidermota S, Wong M, et al. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. Journal of the American College of Cardiology. 2023;81(18):1780-1792. doi:10.1016/j.jacc.2023.02.050
BibTeX
@article{Gilliland2023,
author = {Gilliland, Thomas C and Liu, Yuxi and Mohebi, Reza and Miksenas, Hannah and Haidermota, Sara and Wong, Megan and Hu, Xingdi and Cristino, Joaquim Rosado and Browne, Auris and Plutzky, Jorge and Tsimikas, Sotirios and Januzzi, James L and Natarajan, Pradeep},
title = {Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes},
journal = {Journal of the American College of Cardiology},
year = {2023},
volume = {81},
number = {18},
pages = {1780--1792},
doi = {10.1016/j.jacc.2023.02.050}
}
EUVIMED